NTR -dependent signaling cascade in neurons that not only inhibits axonal growth but also prevents neurotrophins (NT) from stimulating growth. 
The central nervous system shows very limited repair after injury, and this has been postulated to be due in part to the presence of inhibitory products associated with damaged myelin that prevent axonal regeneration (1) . In support, biochemical studies on central myelin have identified two protein fractions that contain inhibitory activity (2) , and monoclonal antibodies that bind to these fractions enhance the growth of axons from cultured sensory and sympathetic neurons into otherwise nonpermissive optic nerve explants (3) . Furthermore, antibody delivery and immunotherapy strategies in animals have provided "proof-of-concept" evidence that some degree of functional recovery can be obtained by counteracting the activity of the myelin inhibitors (4, 5) .
To date, three myelin molecules have been reported to be potent inhibitors of axonal growth, and these are the myelinassociated glycoprotein (MAG) 1 (6, 7) , Nogo-A (8 -10) , and the oligodendrocyte myelin glycoprotein (11) . Remarkably, the low affinity p75 neurotrophin receptor (p75 NTR ) has emerged as the signaling component of a multimeric inhibitory receptor complex that can bind all three myelin inhibitors (12) (13) (14) (15) . Activation of the complex stimulates RhoA, and inhibitors of RhoA, and/or its downstream effector Rho kinase, facilitate growth on myelin substrates (16 -18) .
NGF, BDNF, NT-3, and NT-4 normally promote axonal growth from cultured neurons by activating their specific Trk receptors (19) . However, in the presence of myelin inhibitors, these neurotrophins are prevented from stimulating neurite outgrowth (20) . Also, although beneficial effects of exogenous neurotrophins on the damaged central nervous system have been reported (21) , these tend to be associated with cell survival and limited sprouting. The failure of neurotrophins to promote robust long range axonal regeneration in the damaged nervous system might also be related to the effects of myelin and possibly other inhibitors.
Most interestingly, p75 NTR not only mediates the effects of the myelin inhibitors, it also serves as a low affinity receptor for the above neurotrophins (19) . Recent crystal studies suggest that a neurotrophin dimer can simultaneously engage a Trk receptor and a p75 NTR monomer (22) , and this raises the possibility that neurotrophins might in some instances recruit Trk receptors to inhibitory signaling complexes and thereby undermine their own ability to overcome myelin inhibition. If this hypothesis is correct, then agents that activate Trk receptors in the absence of p75 NTR binding might be expected to promote neurite outgrowth in an inhibitory environment. To test this, we have used a peptide mimetic approach to design a minimalistic version of NT-4 that should be able to activate TrkB but should not be able to form a bridge between TrkB and p75 NTR monomers. We show that in a permissive environment this agent fully mimics the neurite outgrowth promoting activity that natural TrkB agonists BDNF and NT-4 have on cerebellar granule cells. However, unlike the natural TrkB ligands, this * This work was supported in part by Wyeth, and the Biotechnology and Biological Sciences Research Council of Great Britain supported the work in the Doherty laboratory. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. 1 The abbreviations used are: MAG, myelin-associated glycoprotein; TrkA, -B, and -C, receptor tyrosine kinase A, B, and C; p75 NTR , p75 neurotrophin receptor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin 3; NT-4, neurotrophin 4; FGF2, fibroblast growth factor 2; 3T3 cells, embryonic Swiss mouse fibroblast cells; PKA, protein kinase A; PI3K, phosphoinositide 3-kinase; GT1b, trisialoganglioside 1b; GAP-43, growth-associated protein 43. agent can also promote neurite outgrowth when the myelin inhibitory pathway is activated in neurons.
A second independent test of the hypothesis is that agents that interfere with the neurotrophin/p75 NTR interaction should allow neurotrophins to promote neurite outgrowth in an inhibitory environment. NGF and BDNF are very effective at competing for binding to the p75 NTR , but they do not compete effectively for each other's binding their respective Trk receptor (23) . We have taken advantage of the fact that cerebellar neurons do not express TrkA receptors (24) , and we have used NGF to compete for BDNF binding to the p75 NTR in these cells. We find that in the presence of NGF, BDNF acquires the ability to stimulate neurite outgrowth in an inhibitory environment. The same response was found when a monomeric peptide mimetic of a small loop that NGF uses to bind to the p75 NTR was used instead of NGF. These experiments not only provide a plausible explanation as to why endogenous neurotrophins might not be effective at promoting regeneration in the damaged nervous system, they also point to at least two novel strategies for promoting brain repair. For example, agents that activate Trk receptors in the absence of p75 NTR binding might be more effective than neurotrophins at promoting repair. Also, antagonists of the neurotrophin/p75
NTR interaction might allow endogenous neurotrophins, which have long been known to be synthesized in response to injury (25, 26) , to acquire the ability to promote regeneration.
EXPERIMENTAL PROCEDURES
Neurite Outgrowth Assays-Cerebellar neurons isolated from postnatal day 2/3 rat pups were cultured over monolayers of parental 3T3 cells or N-cadherin-expressing 3T3 cells (the LK8 cell line) (27) , essentially as described previously (28) . Monolayers were established by seeding ϳ80,000 cells into individual chambers of an eight-chamber tissue culture slide coated with poly-L-lysine and fibronectin. The cell lines, and monolayers, were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Co-cultures were established by removing the media from the monolayers and seeding ϳ6000 dissociated cerebellar neurons into each well in SATO medium supplemented with 2% fetal calf serum. When looking for trophic factor or peptide stimulation of neurite outgrowth, the monolayers were set up 4 h before the addition of the neurons, and the co-cultures were maintained for ϳ16 h before fixation. The same procedure was followed when looking at the MAG-induced inhibition of neurite outgrowth over Ncadherin-expressing 3T3 cells. However, when looking at MAG inhibition of growth over parental 3T3 cells, the monolayers were established for 24 h prior to addition of the neurons, and the cultures were maintained for ϳ23 h. This increases the basal neurite outgrowth and gives a better window for looking at inhibition of neurite outgrowth by MAG. Following careful fixation with 4% paraformaldehyde, the neurons were immuno-stained with a GAP-43 antibody, and the mean length of the longest neurite per cell was measured for ϳ120 -150 neurons, again as described previously (28) .
Structures-For the purposes of molecular modeling, we primarily made use of the NT-4-TrkB complex (29) that can be found in the Protein Data Bank, code 1HCF. Swiss Protein Data Bank software packages were used to isolate the structure of various motifs from the binding interfaces of the crystals, and Accelrys software was used to generate images.
Reagents-Recombinant human FGF2, NGF, BDNF, and NT-4 were obtained from R&D Systems. K252a was obtained from Calbiochem and used at a final concentration of 100 nM. Recombinant MAG-Fc chimera was obtained from R&D Systems and used at a final concentration of 5-25 g/ml. The monoclonal antibody to GT1b (clone GMR5) was obtained from Seikagaku America and was used at a final concentration of 20 g/ml. A p75 NTR rabbit polyclonal antibody raised against the extracellular domain of the receptor (30) was a kind gift from Dr. Moses Chao and was used at a 1:200 dilution of the serum. The PKA inhibitors KT5720 and H-89 were obtained from Calbiochem and used at final concentration of 200 and 400 nM, respectively. The PI3K inhibitors wortmannin and LY294002 were obtained from Calbiochem, and both were used at final concentrations of 10 M. The Rho kinase inhibitor Y27632 was obtained from Tocris Bristol UK and used at 10 M. All reagents were diluted into the co-culture media and in general added to the cultures just prior to the plating of the neurons. The exception was the antiserum raised against the p75 NTR ; a high density neuronal suspension was treated with a 1:200 dilution of the serum for 60 min, and the neurons were then diluted by a factor of ϳ20 and seeded out for culture. The residual amount of p75 NTR antibody in the cultures was approximately a 1:5000 dilution of the serum. Control experiments showed this antibody had no effect on neurite outgrowth at a dilution of 1:1000.
Peptide Synthesis and Purity-Synthetic peptides were all obtained from a commercial supplier (Multiple Peptide Systems). All peptides were purified to the highest grade by reverse-phase high performance liquid chromatography and obtained at the highest level of purity (Ͼ97%). With all peptides, there was no indication of higher molecular weight species. Where peptide sequences are underlined (see under "Results"), this denotes a peptide that has been cyclized via a disulfide bond between the given cysteine residues. All peptides were acetylated and amide blocked.
RESULTS
Design of a TrkB Antagonist Peptide-In order to design a small agent that might activate TrkB in the absence of p75 NTR binding, we used a peptide mimetic strategy that calls first for the design of an antagonist peptide, with a view to using an established strategy for turning this into an agonist (31) . Peptides that bind to functional sites on TrkB can be identified from the NT-4/TrkB crystal structure (29) . We noted that the SRRGE motif at the amino terminus of NT-4 makes the dominant contact at the a 1 /b 1 interface of the NT-4/TrkB crystal (Fig. 1A) . A constrained cyclic peptide mimetic of this motif (N-Ac-CSRRGEC-NH 2 ), that we call B ANT , shares structural overlap with the natural SRRGE motif (not shown) and would therefore be expected to bind to TrkB. If it does, it should function as a TrkB antagonist. To test this, we cultured postnatal day 2/3 rat cerebellar neurons over monolayers of 3T3 fibroblasts for 16 -17 h. Under these conditions the TrkB agonists NT-4 and BDNF stimulate a robust neurite outgrowth ( Fig. 1 , B and C). This is in accord with results obtained in survival assays and should be viewed alongside evidence that the neurons do not express functional levels of TrkA or TrkC receptors (32) . The B ANT peptide inhibits the NT-4 response in a dose-dependent manner, with a full inhibition seen at ϳ125 M (Fig. 1B) . The SRRGE motif is well conserved in NGF (FHRGE) and NT-3 (SHRGE), and constrained peptide mimetics of these motifs (N-Ac-CFHRGEC-NH 2 and N-Ac-CSHRGEC-NH 2 ) also inhibit the NT-4 response; however, they are considerably less potent (Fig. 1B) . As expected, B ANT was also a very effective BDNF antagonist, with the NGF and NT-3 peptides again being substantially less active (Fig. 1C) .
Concentrations of the B ANT peptide that fully inhibit NT-4 and BDNF responses have no effect on basal neurite outgrowth or neurite outgrowth stimulated by FGF2 or N-cadherin (Fig.  1D ). Also, a linear unconstrained version of the NT-4 motif (N-Ac-SRRGELA-NH 2 ), which would not be expected to share robust structural overlap with the natural motif, does not inhibit the BDNF and NT-4 responses (Fig. 1D ). These data demonstrate that the NT-4 derived B ANT peptide is an effective TrkB antagonist in this model.
Development of a TrkB Agonist Peptide-The SRRGE motif in NT-4 runs anti-parallel to itself in the NT-4 dimer, and this suggests that the "tandem repeat" mimetic approach that we have used to develop N-cadherin agonist peptides (31) might also be used for the development of a TrkB agonist peptide. We anticipated that a tandem repeat of the motif might be constrained within the cyclic N-Ac-CSRRGELAASRRGELC-NH 2 peptide (called the B AG peptide) in a manner that might allow the peptide to engage with, and perhaps stabilize, a TrkB receptor dimer in an active conformation ( Fig. 2A) . In cultures of cerebellar neurons growing at low density over a 3T3 monolayer for 16 -17 h, B AG stimulates neurite outgrowth in a dose-dependent manner with a maximal response seen at 10 g/ml (ϳ6 M) (Fig. 2B) . B AG is as effective as maximally active concentrations of NT-4, BDNF, and FGF2 in promoting neurite outgrowth from cerebellar neurons (Fig. 2C ). Like the response to BDNF (Fig. 1B) , the response to B AG was fully inhibited by the B ANT peptide (Fig. 3) . Likewise, the response to B AG and BDNF is fully inhibited by K252a, a drug that inhibits the tyrosine kinase activity of the Trk receptor (33) . Furthermore, PKA and PI3K activity couple the activated TrkB receptor to neurite outgrowth (34, 35) , and inhibitors of both pathways (KT5720 or H-89 for PKA and wortmannin or LY294002 for PI3K) substantially inhibit the response to BDNF and the B AG (Fig. 3) . All of the above inhibitors have little or no effect on the neurite outgrowth over 3T3 cells or neurite outgrowth stimulated by FGF2 and other agents ( Fig. 1B and Fig. 3 ). These data support the view that BDNF and B AG stimulate neurite outgrowth by activating a common TrkB-dependent signaling cascade in the cerebellar neurons.
B AG , but Not BDNF, Promotes Neurite Outgrowth in an Inhibitory Environment-MAG was the first inhibitory component of myelin to be identified (see Introduction), and it can inhibit neurite outgrowth when presented to neurons as a soluble Fc chimera (36) . To look at MAG inhibition, we cultured cerebellar neurons over monolayers of N-cadherin-expressing fibroblasts, as this gives an enhanced basal outgrowth response over an ϳ16-h culture period when compared with parental 3T3 cells (Fig. 1D) (28) . Under these conditions, B AG and BDNF do not promote additional growth, suggesting that the rate of growth is optimal (Fig. 4) . The MAG-Fc inhibited neurite outgrowth at 5 g/ml, with a more robust inhibition seen at 25 g/ml (Fig. 4) . As reported previously (see Introduction), MAG does not inhibit growth when the Rho kinase inhibitor Y27632 (10 M) is present (Fig. 4) . Also in agreement with Cai et al. (20) we found that BDNF was unable to promote neurite outgrowth in the presence of the MAG-Fc (Fig. 4) . However, the B AG peptide was able to stimulate neurite outgrowth in this inhibitory environment to the extent that it completely circumvented the inhibitory activity of MAG (Fig. 4) . In order to ascertain the robustness of these observations, we repeated the experiments with neurons cultured for a longer period of time (ϳ23 h) over established monolayers of 3T3 fibroblasts. Again, the MAG-Fc inhibits neurite outgrowth in control media and media containing BDNF; however, this inhibition was not seen when the B AG peptide was present (Fig. 5) .
To date, all of the inhibitory molecules in myelin have been reported to signal via p75 NTR . It follows that direct activation of this complex in neurons should also inhibit neurite outgrowth. In this context, direct clustering of p75
NTR with an antibody might be expected to inhibit neurite outgrowth. Indeed, we observed that pretreatment of cerebellar neurons with a p75 NTR polyclonal antibody for 60 min was sufficient to inhibit the subsequent growth of the neurons over the N-cadherin monolayers (Fig. 6) . The response to the p75 NTR antibody was not seen when Rho kinase was inhibited after the pretreatment FIG. 2. Design and testing of a TrkB agonist peptide. A, the native structure of the SRRGELA motif from one monomer of the NT-4 dimer and the ASRRGEL motif from the partner monomer were isolated from the rest of the Protein Data Bank code 1HCF crystal, and these are shown on the left-and right-hand side of the above image, respectively. These can be seen to lie in an anti-parallel manner with reference to each other. We designed a cyclic peptide incorporating both motifs (N-Ac-CSRRGELAASRRGELC-NH 2 ), and we named the peptide "B AG " for TrkB agonist. A modeled structure of the B AG peptide is shown as the central image. This analysis shows that the cyclic peptide has the potential to adopt a structure that would allow for the presentation of two SRRGE-binding motifs in a natural configuration and in an antiparallel manner that we anticipated would allow the peptide to engage with two TrkB receptors simultaneously. B, dissociated cerebellar neurons were cultured over monolayers of control 3T3 fibroblasts in media supplemented with a range of concentrations of the B AG peptide as indicated. C, neurons were grown in the presence of the B AG peptide (at 10 g/ml) or in the presence of maximally active concentrations of NT-4, BDNF, or FGF2 (all at 5 ng/ml) as indicated. B and C, the cultures were maintained for 16 h before being fixed and stained for GAP-43. The mean length of the longest neurite was then determined from 100 to 120 neurons under each culture condition. The results show absolute mean neurite lengths pooled from the given number of independent experiments (shown in brackets). The bar(s) show S.E. These experiments were done in the absence of other agents (control) or in the presence of the Rho kinase inhibitor Y27632 at 10 M, the B AG peptide at 10 g/ml, or BDNF at 5 ng/ml (as indicated). The cultures were maintained for 16 h before being fixed and stained for GAP-43. The mean length of the longest neurite was then determined from 100 to 120 neurons under each culture condition. The results are pooled from at least three independent experiments, and the bars show the S.E. period, confirming that the antibody triggers the same downstream signaling cascade as the natural activators of the receptor (Fig. 6) . BDNF did not have any effect on neurite outgrowth when added after treatment of the neurons with the p75 NTR antibody. In contrast, under the same conditions, the B AG peptide was able to completely circumvent the inhibitory activity of the p75 NTR antibody treatment (Fig. 6 ). These data show that the B AG peptide, but not BDNF, can stimulate neurite outgrowth when administered after the direct activation of the p75 NTR pathway by a p75 NTR antibody.
NGF and an NGF Loop 1 Peptide Allow BDNF to Circumvent MAG Inhibition-We wanted to test if agents that interfere with the BDNF/p75
NTR interaction can influence neurite outgrowth in an inhibitory environment. BDNF and NGF can effectively compete with each other for binding to the p75 NTR , but they are not effective at competing for binding at their respective Trk receptors (23) . When neurons are grown over established 3T3 monolayers for ϳ23 h in media containing 25 g/ml of the MAG-Fc, neither NGF nor BDNF inhibited the MAG response (Fig. 7) ; we can therefore conclude that the neurotrophin-binding site on p75 NTR is not required for the formation and/or function of the p75 NTR inhibitory signaling complex that is activated by the MAG-Fc. Based on this observation, and the fact that p75 NTR is the only NGF receptor expressed by cerebellar neurons, we conclude that NGF is a reasonable agent to use to compete out BDNF binding to p75 NTR in the cerebellar neurons. Effective competition between NGF and BDNF at the p75 NTR receptor requires an ϳ100-fold excess of one neurotrophin to the other (23), and we therefore used BDNF at 1 ng/ml and NGF at 100 ng/ml. In contrast to the results seen when these agents are added in the presence of the MAG-Fc on their own, a significant neurite outgrowth response is seen when BDNF (1 ng/ml) and NGF (100 ng/ml) are added together (Fig.  7) . Increasing the BDNF concentration to 5 and then 10 ng/ml diminished the molar excess of NGF to BDNF and resulted in a considerably smaller neurite outgrowth response, demonstrating the competitive nature of the interaction between the two factors (Fig. 7) . NGF contains four main exposed loops (47) with a considerable body of evidence showing that the TDIKGKE motif that constitutes the first ␤-hairpin loop plays a crucial role in binding to p75 NTR (22, 37) . Constrained peptide mimetics of this motif interact with p75 NTR and would be expected to compete for neurotrophin binding to the receptor (38) . In the present study we tested a constrained monomeric version of the motif (N-Ac-CTDIKGKEC-NH 2 ) for its ability to mimic the effect that NGF has on the BDNF response. When These experiments were done with no other agents added to the media (control), or in the presence of the B AG peptide at 10 g/ml or BDNF at 5 ng/ml. The cultures were maintained for 23 h before being fixed and stained for GAP-43. The mean length of the longest neurite was then determined from 100 to 120 neurons under each culture condition. The results are pooled from three independent experiments, and the bars show the S.E.
FIG. 6. A p75
NTR antibody inhibition of growth can be overcome by B AG but not BDNF. Cerebellar neurons were cultured over monolayers of N-cadherin-expressing 3T3 cells in control media as normal (bar C) or, alternatively, the neurons were pretreated with a p75 NTR antibody (1:200 dilution of serum) for 60 min before being seeded out for culture (bars 1-4) . These antibody-treated neurons were cultured in the absence of other agents (bar 1), or in the presence of Y27632 at 10 M (bar 2), the B AG peptide at 10 g/ml (bar 3), or BDNF at 5 ng/ml (bar 4). The cultures were maintained for 20 h before being fixed and stained for GAP-43. The mean length of the longest neurite was then determined from 100 to 120 neurons under each culture condition. The results are pooled from at least three independent experiments, and the bars show the S.E.
FIG. 7.
Inhibition of the BDNF/p75NTR interaction promotes neurite outgrowth in an inhibitory environment. Cerebellar neurons were cultured over 3T3 monolayers in the presence of the MAG-Fc at 25 g/ml. The culture media were supplemented further with BDNF (1 ng/ml), NGF (100 ng/ml), or BDNF (1-10 ng/ml) plus NGF (100 ng/ml) as indicated. In some experiments a constrained cyclic peptide mimetic of the loop 1 motif in NGF that binds to the p75 NTR (N-Ac-CTDIKGKEC-NH 2 ) was added to the cultures at 100 g/ml in control media or media supplemented with BDNF (1 ng/ml). Cultures were maintained for 23 h before being fixed and stained for GAP-43. The mean length of the longest neurite was then determined from 100 to 120 neurons under each culture condition. The results show the percentage increase in neurite outgrowth over the control value, which was taken as growth in media containing the MAG-Fc alone. The results are pooled from the given number of independent experiments (shown in brackets), and the bars show the S.E. tested at 100 g/ml, the peptide has no effect on neurite outgrowth in the presence of the MAG-Fc (Fig. 7) . However, like NGF, the peptide allowed BDNF to stimulate neurite outgrowth in the presence of the MAG-Fc (Fig. 7) . These data show that NGF can allow BDNF to promote neurite outgrowth in an inhibitory environment, and that this activity can be localized to a ␤-hairpin loop in NGF that is required for p75 NTR binding.
B AG Signaling in an Inhibitory Environment Is Dependent on
TrkB-We wanted to test if, in the presence of the MAG-Fc, the B AG peptide response was dependent on the TrkB receptor function. Neurons were again cultured on established 3T3 monolayers over a 23-h assay period in media supplemented with 25 g/ml of the MAG-Fc. The first observation of note is that in the presence of BDNF (5 ng/ml), but not NGF (5 ng/ml), the neurite outgrowth response to the B AG peptide is substantially inhibited (Fig. 8) . This would be expected if B AG and BDNF share a common binding site on the TrkB receptor. There was also no significant response to the B AG peptide when K252a (100 nM) was included in the media or when the PI3K inhibitor LY294002 (10 M) or the PKA inhibitor KT5720 (200 nM) were included. All of these agents have been shown to inhibit TrkB responses (Fig. 3) . None of these agents had any effect on the basal neurite outgrowth in control media or in media supplemented with the MAG-Fc (data not shown).
DISCUSSION

p75
NTR is enigmatic; it was first identified as a receptor for the neurotrophins but has more recently emerged as the key signaling component of a receptor complex that binds at least three myelin inhibitors. Neurotrophin activation of p75 NTR can induce diverse cellular responses that range from promoting cell survival to inducing cell death (19) . The picture for neuronal responsiveness to neurotrophins within an inhibitory environment is less clear, as under these circumstances p75 NTR also serves as the signaling component of an inhibitory receptor complex that contains the glycosylphosphatidylinositol-linked Nogo-66 receptor and LINGO-1 (12-15) . Neurotrophins do not normally promote neurite outgrowth when myelin inhibitors are present (20) . This is a very serious consideration that might limit the therapeutic value of this class of molecule and explain, at least in part, why neurotrophins have not been developed as effective therapeutic agents. It has been shown recently (22) that neurotrophins can only engage a single p75 NTR monomer and, in principle, can form a complex that contains both a Trk receptor and a p75 NTR monomer. Prior to this observation, we postulated that in an inhibitory environment neurotrophins might compromise their own ability to promote regeneration by recruiting the Trk and p75 NTR receptors to an inhibitory signaling complex. One way to test this would be to see if a molecule that activates TrkB in the absence of p75 NTR binding promotes growth in an inhibitory environment. Another way to test this would be to see if BDNF acquires the ability to promote growth in an inhibitory environment when its ability to interact with the p75 NTR is compromised. Small peptide mimetics of linear binding motifs in neurotrophins can serve as antagonists (39 -41) , and in some instances multimeric versions of the motifs have agonist activity (42) (43) (44) . Although these studies have looked at the effects of peptides on neuronal responses in a permissive environment, they did not address the fundamentally different question of why neurotrophins fail to promote growth in an inhibitory environment. Although our aim was not to make an agonist that interacts exclusively with TrkB (relative to TrkA and TrkC), nonetheless we noted that the amino-terminal regions of the neurotrophins are responsible for conferring Trk receptor specificity (45) . In the NT-4/TrkB crystal, the SRRGE motif at the amino terminus of the neurotrophin makes the substantive contact with the membrane proximal Ig domain of the TrkB receptor, suggesting that peptide mimetics based around this motif might be developed as both antagonists and agonists. Indeed, we have found that a simple constrained mimetic (N-Ac-CSRRGEC-NH 2 ), which we call B ANT , serves as a very effective NT-4 and BDNF antagonist. B ANT had no effect on similar responses stimulated by a variety of other agents. The parsimonious interpretation of the data is that B ANT is binding to the TrkB receptor and interfering with the ability of the natural ligand to activate the receptor. The RGE triplet in the SRRGE motif is conserved in TrkA and TrkC ligands, and the equivalent peptides from NGF and NT-3 also function as BDNF/NT-4 antagonists. However, they were considerably less effective than the NT-4 peptide, and this suggests that there is some degree of binding specificity even in these short motifs. Therefore, it would seem probable that B ANT might also interact to some extent with the other Trk receptors but perhaps less well than with the TrkB receptor.
When a "tandem repeat" strategy that we previously developed for making an N-cadherin agonist peptide is used (31) , and a dimeric version of the B ANT peptide is made, it functions as a full agonist in the neurite outgrowth assay. The B AG peptide was as effective as BDNF, NT-4, and a variety of other agents at stimulating neurite outgrowth from cerebellar neurons.
When neurons are grown for ϳ16 h over N-cadherin-expressing 3T3 cell monolayers, or for ϳ23 h over 3T3 cell monolayers, a robust neurite outgrowth response is measured. In both instances, soluble MAG-Fc inhibited growth by around 40 -50%. A similar inhibition of growth was seen when neurons were treated with a p75 NTR antibody. In both cases, Rho kinase activity seems to be central to this suppression of growth as the responses could be fully inhibited by the Rho kinase inhibitor, Y27632. As reported previously (see Introduction), BDNF was unable to promote neurite outgrowth in the presence of the MAG-Fc or after the direct activation of p75 NTR with a p75 antibody. However, the B AG peptide was able to stimulate growth in both inhibitory environments to the extent that inhibition by both the MAG-Fc and the p75 NTR antibody was fully circumvented. An antibody to GT1b also inhibits neurite outgrowth by activating the MAG receptor complex in neurons (46); we have confirmed this observation and also find that this inhibitory response can also be circumvented by the B AG peptide but not BDNF (not shown).
B AG was rationally designed to be a TrkB agonist, and the possibility that B AG might be stimulating growth via a non-Trk pathway is extremely unlikely as several lines of evidence suggest that this peptide is functioning as a TrkB agonist. First, the response to the peptide can be fully inhibited by a monomeric version of the same binding motif that has been shown to function as a TrkB antagonist. Second, the response to B AG is fully inhibited by K252a, an established and relatively specific inhibitor of the tyrosine kinase activity of the Trk receptor family (33) . In addition, PKA and PI3K antagonists inhibited both B AG and BDNF responses in the absence of any substantial effect on basal neurite outgrowth or neurite outgrowth stimulated by FGF2. Finally, in the presence of the MAG-Fc, BDNF (but not NGF) can compete out the B AG response, suggesting that they interact with a common receptor. Thus, by several independent criteria it would appear that B AG -stimulated neurite outgrowth requires the function of the TrkB receptor and its associated signaling cascade. Nonetheless, peptides of this size and affinity are rarely good tools for binding and biochemical studies, even though they work well in biological assays. Indeed, we have been unable to obtain direct evidence for B AG binding to TrkB. For this reason, it was essential to use an independent approach to test further the hypothesis.
The hypothesis is that BDNF is unable to promote growth in an inhibitory environment because it can bind to both TrkB and p75 NTR ; this can be independently tested by determining whether agents that compete for the BDNF/p75 NTR interaction allow BDNF to stimulate growth in the inhibitory environment. As NGF will compete effectively for BDNF binding to the p75 NTR , but not TrkB, the addition of NGF into the cultures can clearly give an insight into this question. In this context, p75 NTR is the only NGF receptor in cerebellar neurons, and it is the only known target for which NGF and BDNF can effectively compete for binding. The results clearly show that when NGF is added to the cultures at an ϳ100-fold molar excess, BDNF acquires the ability to stimulate considerable neurite outgrowth in the presence of the MAG-Fc. The BDNF response (ϳ40% increase over control) was not as good as that seen with the B AG peptide under the same conditions (ϳ60% increase), and this probably reflects the fact that 1 ng/ml BDNF is a suboptimal concentration for axonal growth. It is self-evident that as the BDNF concentration increases, NGF will become less effective at competing out its binding to the p75 NTR . When the BDNF concentration is increased in the presence of NGF (held at 100 ng/ml) and the MAG-Fc, the neurite outgrowth response decreases in a dose-dependent manner. These results establish the competitive nature of an NGF/BDNF interaction in the inhibitory environment, and clearly support the hypothesis that BDNF acquires the ability to promote growth because NGF prevents it from binding to the p75 NTR . The above observation with NGF and BDNF might allow some insights into why a BDNF/p75 NTR interaction prevents growth. In a purely "signaling" model, BDNF binding to the p75 NTR might generate a signal that compromises TrkB signaling, and other neurotrophins might also be expected to be able to deliver this signal. The fact that NGF does not inhibit the response to the TrkB agonists would tend to argue against this.
However, signaling by NGF and BDNF via the p75 NTR might not be equivalent in terms of modulating TrkB function. Nonetheless, another possibility is a "scaffold" model where the ability of BDNF to bind to both p75 NTR and TrkB, perhaps simultaneously, would play a role in recruiting TrkB into a p75 NTR inhibitory signaling complex. In turn, this might facilitate cross-talk between the receptors in a manner that allows the inhibitory signal to dominate. Indeed, recent crystal structures suggest that a neurotrophin dimer might be able to bind simultaneously a Trk and p75 NTR monomer (22) . The observation that NGF allows BDNF to promote growth in an inhibitory environment, most probably by competing for BDNF/p75 NTR binding, would fit with such a model. In support, NGF contains four exposed ␤-hairpin loops (47) , with a considerable body of evidence showing that the TDIKGKE motif that constitutes loop 1 plays a crucial role in binding to p75 NTR (22, 37) . A constrained monomeric version of the motif (N-Ac-CT-DIKGKEC-NH 2 ) behaved in the same manner as NGF and allowed BDNF to promote neurite outgrowth in the presence of the MAG-Fc. Thus, this novel activity of NGF can be localized to a ␤-hairpin loop that is required for p75 NTR binding. In summary, within an inhibitory environment, p75
NTR is the signaling component of an inhibitory receptor complex. The experiments in this study have been designed to test the hypothesis that BDNF fails to promote neurite outgrowth in such an inhibitory environment because it binds to both the TrkB receptor and p75 NTR and perhaps thereby recruits the Trk receptor to the inhibitory complex. The ability of the B AG peptide to promote growth in this environment would be accounted for by its inability to bind to p75 NTR , with the ability of BDNF to promote growth when NGF (or the NGF loop 1 peptide) is added accounted for by competition for binding to p75 NTR . The TrkB receptor has been validated in a number of studies as a therapeutic target for brain repair (48 -50) . However, as with other "large molecule" strategies, continuous delivery of effective levels of BDNF and/or NT-4 to the vulnerable neurons presents a considerable therapeutic challenge. Our studies now suggest that the use of these natural ligands of the receptor in a therapeutic context might also be compromised by the fact that they can engage with p75 NTR in neurons. It follows that small molecule agonists of the TrkB receptor that do not bind to p75 NTR might have therapeutic potential in a wide range of applications. Likewise, as neurotrophins are often present at injury sites (25, 26) , their ability to promote regeneration might be enhanced by agents that inhibit their binding to p75 NTR . Both types of agent might be useful for combating neurodegenerative conditions such as Alzheimer's and Parkinson's disease and/or promoting brain repair following injury associated with events like stroke or spinal cord hemi-section (51, 52) . The peptide mimetics used in the present study were designed to test an hypothesis and not as drugs for animal studies. Nonetheless, rational approaches can be adopted for the development of peptides into compounds suitable for such studies.
